A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Official Title

A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

Summary:

This is an open-label, single-arm, study of idasanutlin monotherapy in participants with hydroxyurea (HU)-resistant/intolerant Polycythemia vera (PV).

Trial Description

Primary Outcome:

  • Composite Response at Week 32 for Ruxolitinib-Naïve Participants With Splenomegaly at Baseline
  • Hematocrit (Hct) Control Without Phlebotomy at Week 32 for Ruxolitinib-Naïve Participants Without Splenomegaly at Baseline
  • Hct Control Without Phlebotomy at Week 32 for All Ruxolinitib-Naïve Participants (With and Without Splenomegaly)
Secondary Outcome:
  • Response per Modified European Leukemia Net (ELN) Criteria at Week 32 for Ruxolitinib-Naïve Participants and All Participants Irrespective of Prior Ruxolitinib Exposure
  • Duration of Response, Including Percentage of Participants With Durable Response Lasting at Least 12 Weeks
  • Composite Response at Week 32 for Participants With Splenomegaly at Baseline Irrespective of Prior Ruxolitinib Exposure
  • Hct Control Without Phlebotomy at Week 32 for Participants Without Splenomegaly at Baseline Irrespective of Prior Ruxolitinib Exposure
  • Hct Control Without Phlebotomy at Week 32 for All Participants (With and Without Splenomegaly) Irrespective of Prior Ruxolitinib Exposure
  • Hct Control Without Phlebotomy at Week 32 for All Participants (With and Without Splenomegaly) Who Had Prior Ruxolitinib Exposure
  • Percentage of Participants With Abnormal Clinical Laboratory Findings
  • Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
  • Eastern Cooperative Oncology Group (ECOG) Performance Status
  • Percentage of Participants With Abnormal Electrocardiogram (ECG) Findings, Vital Signs, and Physical Findings
  • Percentage of Participants With Concomitant Medications
  • Maximum Serum Concentration Observed (Cmax)
  • Trough Concentration (Ctrough)
  • Time of Maximum Concentration Observed (tmax)
  • Clearance (CL)
  • Apparent clearance (CL/F)
  • Volume or Apparent Volume of Distribution (Vdss/F)
  • Area under the curve (AUC)
  • Half-life (t1/2)
  • Baseline and Mean Change from Baseline Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
  • Baseline and Mean Change from Baseline European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
  • Baseline and Mean Change from Baseline Patient Global Impression of Change (PGIC)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society